Big Call Screening: Nasdaq, AXA, Sanofi
Reading Time: 2 minutes
Currently, the price action of Sanofi appears bullish. The French pharmaceutical company is strong in its core business areas of vaccines, oncology, and immunology products, and it has an exciting development pipeline. As it gains further market share in the vaccine segment thanks to the RSV vaccine Beyfortus and anticipates significant revenue increases due to the expanded approval of the mega blockbuster Dupixient for the treatment of COPD, Sanofi is expected to significantly improve its results in 2025. The Nasdaq (NDAQ) is likely to benefit...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
